Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer

European Journal of Cancer

Volumn 46, Issue 8, 2010, Pages 1438-1444

  Karamitopoulou, Eva ^a,c   Pallante, Pierlorenzo ^b   Zlobec, Inti ^c   Tornillo, Luigi ^c   Carafa, Vincenza ^c   Schaffner, Thomas ^d   Borner, Markus ^e   Diamantis, Ioannis ^a   Esposito, Francesco ^b   Brunner, Thomas ^d   Zimmermann, Arthur ^d   Federico, Antonella ^f   Terracciano, Luigi ^c   Fusco, Alfredo ^f  

^a UNIVERSITY OF ATHENS   (Greece)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f CNR   (Italy)

Author keywords

CBX7; Pancreatic cancer; PanIN; Prognosis; Tissue microarray

Indexed keywords

POLYCOMB GROUP PROTEIN; POLYCOMB GROUP PROTEIN CBX7; UNCLASSIFIED DRUG; UVOMORULIN; BMI1 PROTEIN; CADHERIN; CBX7 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; PROTEIN MICROARRAY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; PROGNOSIS; PROTEIN ARRAY ANALYSIS; REPRESSOR PROTEINS; ROC CURVE; YOUNG ADULT; POLYCOMB REPRESSIVE COMPLEX 1;

EID: 77951877780     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.01.033     Document Type: Article

References (30)

1. Gil J., Bernard D., and Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 24 (2005) 117-125
2. Lund A.H., and van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16 (2004) 239-246
3. Van Kemenade F.J., Raaphorst F.M., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 (2001) 3896-3901
4. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100 (2003) 11606-11611
5. Lessard J., and Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003) 255-260
6. Pallante P., Federico A., Berlingieri M.T., et al. Loss of CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 68 (2008) 6770-6778
7. Federico A., Pallante P., Bianco M., et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 69 (2009) 7079-7087
8. Kleeff J., Michalski C., Friess H., and Büchler M.W. Pancreatic cancer: from bench to 5-year survival. Pancreas 33 (2006) 111-118
9. Cameron J.L., Crist D., Sitzmann J.V., et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161 (1991) 120-124
10. Mannell A., Weiland L.H., Van Heerden J.A., and Ilstrup D.M. Factors influencing survival after resection for ductal adenocarcinoma of the pancreas. Ann Surg 203 (1986) 403-407
11. Hruban R.H., Goggins M., Parsons J., and Kern S.E. Progression model for pancreatic cancer. Clin Cancer Res 6 (2000) 2969-2972
12. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (2001) 579-586
13. Klöppel G., Hruban R.H., Longnecker D.S., Adler G., Kern S.E., and Partanen T.J. Ductal adenocarcinoma of the pancreas. Pathology and genetics. In: Hamilton S.R., and Aaltonen L.A. (Eds). Tumors of the digestive system, World Health Organisation classification of tumors (2000), IARCP Press, Lyon 221-230
14. Hruban R.H., Wilentz R.E., and Kern S.E. Genetic progression in the pancreatic ducts. Am J Pathol 156 (2000) 1821-1825
15. Hanley J. Receiver operating characteristic (ROC) methodology: the state of the art. Critical Rev Diagn Imagin 29 (1989) 307-337
16. Zlobec I., Steele R., Terracciano L., Jass J.R., and Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 60 (2007) 1112-1116
17. Torhorst J., Bucher C., Kononen J., et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
18. Engelsen I.B., Mannelqvist M., Stefansson I.M., et al. Low BMI-1 expression is associated with an activated BMI-1 driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer 98 (2008) 1662-1669
19. Kozakowski N., Soleiman A., and Pammer J. BMI-1 expression is inversely correlated with the grading of renal clear cell carcinoma. Pathol Oncol Res 14 (2008) 9-13
20. Bachmann I.M., Puntervoll H.E., Otte A.P., and Akslen L.A. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 21 (2008) 583-590
21. Schutte M., Hruban R.H., Geradts J., et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57 15 (1997) 3126-3130
22. Douglas D., Hsu J.H., Hung L., et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res 68 16 (2008) 6507-6515
23. Xu C.R., Lee S., Ho C., Bommi P., et al. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. Mol Cancer Res 7 (2009) 1937-1945
24. Gil J., Bernard D., Martinez D., and Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 6 (2004) 67-72
25. Scott C.L., Gil J., Hernando E., Teruya-Feldstein J., et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 104 (2007) 5389-5394
26. Wood L.J., Maher J.F., Bunton T.E., and Resar L.M. The oncogenic properties of the HMG-1 gene family. Cancer Res 60 (2000) 4256-4261
27. Baldassarre G., Fedele M., Battista S., et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-5 pathway. Proc Natl Acad Sci USA 98 (2001) 7970-7975
28. Fedele M., Pentimalli F., Baldassare G., et al. Transgenic mice overexpressing the wild-type form of HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24 (2005) 3427-3435
29. Fedele M., Fidanza V., Battista S., et al. Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 66 (2006) 2536-2543
30. Johnson D.G., and Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 6 (2006) 731-738